Lipocine Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2021. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products. It had not generated product-sales revenue.
Financial performance and position
- Q3 revenue: $55,000 in license revenue, versus none in Q3 2020. Q3 operating expenses were $3.59 million; net loss was $3.08 million ($0.03 per share), compared with $4.38 million of expenses and a $4.31 million net loss ($0.07 per share) a year earlier.
- Nine-month results: Revenue was $55,000. Operating expenses were $9.69 million, down from $13.19 million; net loss was $13.26 million ($0.15 per share), versus $16.45 million ($0.32 per share) in 2020.
- Cash flow: Nine-month operating cash use was $13.41 million, compared with $11.62 million in 2020. Investing cash use was $34.06 million, primarily purchases of marketable securities; financing provided $27.76 million.
- Liquidity: At September 30, cash and cash equivalents were $4.52 million and marketable securities were $34.15 million, totaling $38.66 million of unrestricted cash and investments. Current assets were $40.37 million and current liabilities $6.43 million.
- Debt and obligations: The balance sheet reported $3.14 million of current debt and no non-current debt. The SVB loan matures June 1, 2022; scheduled principal remaining was $2.5 million, excluding the final payment charge. The Clarus settlement liability was $1.5 million, payable in 2022 and 2023.
- Margins: Product sales were nil and license revenue was immaterial relative to operating expenses; operating and gross margins are therefore not meaningful indicators of a commercial business at this stage.
Material changes versus comparable periods
- Q3 net loss improved by about $1.23 million year over year, while nine-month net loss improved by about $3.20 million. Lower R&D and administrative expenses contributed; the nine-month comparison also reflects a $3.03 million warrant fair-value loss in 2020 versus a $0.51 million gain in 2021.
- Nine-month R&D expense fell $1.86 million, mainly from lower LPCN 1144 and TLANDO costs, partly offset by new or higher spending on LPCN 1154, LPCN 1148 and other programs. G&A fell $1.64 million, principally due to lower legal and stock-compensation costs.
- Cash and marketable securities totaled $38.66 million, versus $19.67 million at December 31, 2020. The increase reflects equity financing, including $26.8 million net proceeds from the January 2021 offering and $3.4 million from ATM sales; common shares outstanding rose to 88.29 million from 70.04 million.
Outlook, developments and risks
- Management estimated existing capital resources would fund projected operations through at least September 30, 2022, but said additional capital will be needed before or after that date. The estimate depends on operating plans, clinical activity and other assumptions; failure to raise funds could threaten continuing operations.
- On October 14, 2021, after quarter-end, Lipocine entered an exclusive U.S. TLANDO license with Antares and received an $11 million upfront payment. The agreement includes conditional $5 million payments in 2025 and 2026, potential sales milestones up to $160 million, and tiered royalties. Antares may also license TLANDO XR by March 31, 2022. These terms are contingent and the upfront payment was not part of September 30 cash.
- TLANDO had tentative FDA approval but could not receive final approval before March 27, 2022, when Clarus’s JATENZO exclusivity expires. The FDA indicated a Class 1 resubmission review goal of two months. Required post-marketing studies include a label-comprehension study and a one-year adrenal-insufficiency study; Antares is responsible for these studies under the agreement.
- LPCN 1144’s Phase 2 LiFT study reported positive liver-fat and histology findings, but the study was not powered to establish statistical significance for secondary endpoints, and fibrosis effects require confirmation. The ongoing extension study had enrolled 25 subjects; topline results were expected mid-2022. Management planned an FDA meeting on the development path and reported Fast Track designation in November 2021.
- Key risks include clinical and regulatory uncertainty, dependence on financing and collaborators, potential dilution, competition in testosterone therapies, and limited ability to commercialize without partner or internal sales capabilities. The company reported 13 employees and limited authorized-share capacity for future equity issuance.
- The Clarus patent litigation and interference proceeding were settled for $4.0 million, with no future royalties between the parties. A separate shareholder securities class action remained pending; a motion-to-dismiss hearing was scheduled for January 12, 2022. No liability was recorded because a loss was not considered probable or estimable.
Most important facts to verify
- Whether TLANDO receives final FDA approval after the March 2022 exclusivity period and the timing and requirements of any launch.
- How the $11 million Antares payment and subsequent license economics affect cash runway, and whether contingent milestones or royalties are achieved.
- Actual cash burn and financing needs relative to management’s runway estimate through September 30, 2022.
- Further LPCN 1144 data and FDA feedback, including confirmation of histology and fibrosis findings in larger studies.
- Outcome of the shareholder class action, settlement-payment schedule, and any material changes in litigation exposure.
- Potential dilution and remaining capacity under the ATM and authorized common shares.